Zeus Hygia Lifesciences announced publication of a clinical study on Metaberine®, a bio-optimised berberine formulation, in the International Journal of Clinical Trials. The randomized, double-blind, placebo-controlled crossover trial of 36 healthy adults found that 200 mg daily dosing significantly improved markers of metabolic health including fasting glucose, GLP-1 response, and lipid parameters, with no adverse events reported.
4 of 5 articles were readable. Headline only, no body text retrieved, for: asiafoodjournal.com. Nothing below is drawn from those outlets beyond their headline.
Who reported it
- asiafoodjournal.comUNCLASSIFIED
- business-standard.comUNCLASSIFIED
- theprint.inUNCLASSIFIED
- thewire.inUNCLASSIFIED
- tribuneindia.comUNCLASSIFIED
References
- asiafoodjournal.comZeus Hygia’s Metaberine® clinical study published, demonstrating metabolic health benefits at just 200 mg dailyScreenshot as publishedOriginalcaptured 2026-08-17T18:29:09
- business-standard.comZeus Hygia's Metaberine® Clinical Study Published, Demonstrating Metabolic Health Benefits at just 200 mg DailyScreenshot as publishedOriginalcaptured 2026-08-17T18:29:09
- theprint.inZeus Hygia’s Metaberine® Clinical Study Published, Demonstrating Metabolic Health Benefits at just 200 mg DailyScreenshot as publishedOriginalcaptured 2026-08-17T18:29:09
- thewire.inZeus Hygia’s Metaberine® Clinical Study Published, Demonstrating Metabolic Health Benefits at just 200 mg DailyScreenshot as publishedOriginalcaptured 2026-08-17T18:29:09
- tribuneindia.comZeus Hygias Metaberine® Clinical Study Published, Demonstrating Metabolic Health Benefits at just 200 mg DailyScreenshot as publishedOriginalcaptured 2026-08-17T18:29:09
Carried by multiple outlets
- Zeus Hygia Lifesciences announced publication of a clinical study evaluating Metaberine®, a bio-optimised berberine formulation developed using proprietary BioSOLVE® Technologybusiness-standard.com, theprint.in, thewire.in, tribuneindia.com
- The study was published in the International Journal of Clinical Trialsbusiness-standard.com, theprint.in, thewire.in, tribuneindia.com
- The study was a randomized, double-blind, placebo-controlled crossover trialbusiness-standard.com, theprint.in, thewire.in, tribuneindia.com
- The study evaluated 36 healthy adults with fasting glucose levels of 100-125 mg/dLbusiness-standard.com, theprint.in, thewire.in, tribuneindia.com
- Participants received Metaberine® 200 mg or placebo once daily for 14 days, followed by a seven-day washout periodbusiness-standard.com, theprint.in, thewire.in, tribuneindia.com
- Fasting glucose decreased by 9.08 mg/dL with Metaberine® compared with 1.36 mg/dL with placebobusiness-standard.com, theprint.in, thewire.in, tribuneindia.com
- and 4 more, not shown




